医学
创伤性脑损伤
重症监护医学
水肿
脑水肿
冲程(发动机)
临床试验
脑水肿
麻醉
药理学
神经科学
内科学
精神科
机械工程
生物
工程类
作者
Melissa Pergakis,Neeraj Badjatia,J. Marc Simard
标识
DOI:10.1080/14656566.2021.1876663
摘要
Introduction: Cerebral edema is a common complication of multiple neurological diseases and is a strong predictor of outcome, especially in traumatic brain injury and large hemispheric infarction.Areas Covered: Traditional and current treatments of cerebral edema include treatment with osmotherapy or decompressive craniectomy at the time of clinical deterioration. The authors discuss preclinical and clinical models of a variety of neurological disease states that have identified receptors, ion transporters, and channels involved in the development of cerebral edema as well as modulation of these receptors with promising agents.Expert opinion: Further study is needed on the safety and efficacy of the agents discussed. IV glibenclamide has shown promise in preclinical and clinical trials of cerebral edema in large hemispheric infarct and traumatic brain injury. Consideration of underlying pathophysiology and pharmacodynamics is vital, as the synergistic use of agents has the potential to drastically mitigate cerebral edema and secondary brain injury thusly transforming our treatment paradigms.
科研通智能强力驱动
Strongly Powered by AbleSci AI